|
|
|
|
|
|
|
Free Newsletters
Archive
My Subscriptions
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers
Regional News
US & Canada
Biotech Bay
Biotech Beach
Genetown
Pharm Country
BioCapital
BioMidwest
Bio NC
BioForest
Southern Pharm
BioCanada East
US Device
Europe
Asia
Market Summary
News
IPOs
Company Profiles
Companies
Events
Research Store
Biotech Events
Post an Event
Real Estate
Business Opportunities
|
|
|
|
|
News | News By Subject | News by Disease |
News By Date | Search News
|
|
|
2/13/2013 8:55:51 AM
Clinical stage biopharmaceutical company BIND Biosciences Inc. has received $8.7 million in equity financing, federal documents show. Cambridge, Mass.-based BIND, which develops nanoparticle technology that concentrates a drug right at the site of cancer cells (which minimizes exposure to the healthy tissue and decreases side effects), received the funding from a total of 20 investors. In October 2011, BIND received a $47.35 million financing from RUSANO, a billion dollar investment fund focused on nanotechnology, existing investors and new investors. Co-founded in 2007 by Omid Farokhzad, associate professor at Harvard Medical School and physician-scientist at Brigham and Women’s Hospital, and serial entrepreneur Robert Langer, BIND also has its own proprietary drug candidates. The company’s lead compound, BIND-014, is in Phase 1 clinical testing.
|
|
|
|
|
|
|
|
|
|
|